<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538302</url>
  </required_header>
  <id_info>
    <org_study_id>92.121.505</org_study_id>
    <nct_id>NCT02538302</nct_id>
  </id_info>
  <brief_title>Minirin Versus Oxybutynin for Nocturnal Enuresis in Children</brief_title>
  <official_title>Minirin Versus Oxybutynin for Nocturnal Enuresis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hormozgan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hormozgan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nocturnal enuresis is among the most common disorders in children. The aim of current study
      was to compare the efficacy and safety of Minirin and oxybutynin for treatment of nocturnal
      enuresis in children in Bandar Abbas in 2014.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nocturnal enuresis is among the most common disorders in children. Several pharmacological
      and non-pharmacological treatments are available for nocturnal enuresis. Studies for reaching
      the best pharmacological treatment for this disorder are continuing. The aim of current study
      was to compare the efficacy and safety of Minirin and oxybutynin for treatment of nocturnal
      enuresis in children in Bandar Abbas in 2014.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ù‘Frequency of nocturnal enuresis</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with nocturnal enuresis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of urinary incontinency</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with urinary incontinency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of urgency</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with urgency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Xerostomia</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Xerostomia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Xerophthalmia</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Xerophthalmia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Blurred vision</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Blurred vision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Dysphagia</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Dysphagia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of constipation</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with constipation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Diarrhea</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Diarrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Headache</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Headache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Seizure</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Seizure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Epistaxis</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Epistaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Abdominal pain</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Abdominal pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Vomiting</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Vomiting</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Ear ache</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Ear ache</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Rhinitis</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Rhinitis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Chest pain</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Chest pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Increase in appetite</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with Increase in appetite</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Nocturnal Enuresis</condition>
  <arm_group>
    <arm_group_label>Minirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 microgram per day for 2 months, then 60 microgram per day for 2 months, then 60 microgram every two days for two months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxybutynin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mg Oxybutynin twice a daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minirin</intervention_name>
    <description>Minirin 5 to 10 mg daily for 6 months</description>
    <arm_group_label>Minirin</arm_group_label>
    <other_name>Desmopressin acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxybutynin</intervention_name>
    <description>Oxybutynin 5 to 10 mg daily for 6 months</description>
    <arm_group_label>Oxybutynin</arm_group_label>
    <other_name>Ditropan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;5 years old

          -  Nocturnal enuresis

          -  Candidate for pharmacological treatment

        Exclusion Criteria:

          -  Children who their parents did noted filled the informed consent form

          -  Impossibility of follow up during the study period

          -  History of seizure

          -  History of rheumatologic disorders such as sjogren's disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hamidreza Mahboobi, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hormozgan University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shahid Mohammadi hospital</name>
      <address>
        <city>Bandar Abbas</city>
        <state>Hormozgan</state>
        <zip>79176</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2015</study_first_submitted>
  <study_first_submitted_qc>August 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>August 29, 2015</last_update_submitted>
  <last_update_submitted_qc>August 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hormozgan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Hamidreza Mahboobi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Minirin</keyword>
  <keyword>Oxybutynin</keyword>
  <keyword>Nocturnal enuresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enuresis</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Nocturnal Enuresis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxybutynin</mesh_term>
    <mesh_term>Mandelic Acids</mesh_term>
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

